NT5E and colorectal carcinoma: Accordingly, future efforts assessing CD73 expression to the CMS groups (e.g., CMS1, CMS2, CMS3, CMS4) may provide a better understanding of CD73 in CRC and the possible molecular and genetic alterations that drive its downregulation and/or overexpression.